Global OTC Drug Market Analysis by Kalorama Information Now Available at MarketPublishers.com
08 Jun 2012 • by Natalie Aster
LONDON – A host of pharmaceutical companies seeking more revenue and international exposure have found an opportunity in the development of over-the-counter (OTC) drugs. OTC drugs are sold to consumers by convenience and grocery stores, as well as via a new range of outlets including online sales and catalog.
Of the various developments in the over-the-counter (OTC) drug market, there has been a notable increased interest in consumer care divisions by top companies such as Sanofi and Boehringer Ingelheim. The switch of Allegra to OTC was an important strategic move for Sanofi and one of the key reasons for the purchase of Chattem in 2009. Boehringer Ingelheim also expanded its investment in OTC with the creation of Rx-to-OTC switch unit in 2010, increasing global expansion – specifically in Asian markets, and new OTC product introductions in categories with limited treatments.
New research report “The World Market for Over The Counter (OTC) Drugs” developed by Kalorama Information provides a worldwide overview of the OTC drug market, with special emphasis on the U.S., Japan, Germany, and other key markets. It includes the incidence of conditions which are often treated with OTC medicines, health statistics related to the industry, birth rates, world population, populations by region and issues affecting the market as a whole. The five market segments provide an overview of demographics, overview of products available in each region – the Asia Pacific and Africa, Europe, North America and South America, market estimates and forecasts through 2015. Additionally, the competitive landscape along with the profiles of major providers is also provided.
Market segments discussed include: analgesics; allergy, cough, cold, flu remedies; gastrointestinal remedies; dermatologics; others (smoking cessation products, sleepaids, hair growth remedies, diet aids, etc.).
The World Market for Over The Counter (OTC) Drugs
Published: May, 2012
Price: US$ 3.995,00
More new research reports by the publisher can be found at Kalorama Information page.